Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Shockwave ™ vs Endartériectomie chirurgicale pour la sténose de l'artère fémorale grave calcifiée: comparaison de l'efficacité, de la sécurité et des résultats à long terme (Shockify)

4 novembre 2026 mis à jour par: Baylor Research Institute

The investigators hypothesize that Shockwave with DCB is non-inferior to surgical endarterectomy for common femoral artery (CFA) stenosis with regard to primary efficacy and safety endpoints. The study will challenge the current guideline that recommends common femoral endarterectomy (CFE) as the primary treatment for symptomatic CFA stenosis.

Aperçu de l'étude

Description détaillée

This is a pilot, prospective, randomized clinical trial. This trial compares patients with severe symptomatic moderate to severe calcified CFA stenosis undergoing traditional gold standard CFA endarterectomy to innovative technique of endovascular treatment using Shockwave™ Intra vascular Lithotripsy (IVL) using M5+ balloon with Drug coated balloon to achieve removal and debulking of plaque and achieve luminal gain. Patients who meet inclusion criteria will be informed and consented by a clinical coordinator if they wish to participate in the trial. If participants are candidates for surgery, they will then be randomized into one of two cohorts, receiving either Shockwave™ IVL + DCB (drug-coated balloon) procedure or a standard surgical endarterectomy. The study compares the 1-year efficacy and 6-month safety outcomes post-procedure for patients with severe, symptomatic CFA stenosis receiving Shockwave™ IVL with DCB versus surgical endarterectomy.

Type d'étude

Interventionnel

Inscription (Estimé)

60

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Texas
      • Plano, Texas, États-Unis, 75093
        • Baylor Scott & White The Heart Hospital - Plano

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

A patient will be eligible for inclusion in this study if he or she meets all of the following criteria (confirmed by core lab):

  1. CFA atherosclerotic stenosis 60-100%
  2. Moderate to severe calcification reported on imaging
  3. Lifestyle-limiting intermittent claudication (IC) or chronic limb-threatening ischemia (CLTI) as described by Rutherford chronic limb ischemia (CLI) category 2-5
  4. Failing conservative therapy
  5. Operative candidate for CFE prior to enrollment
  6. ≥18 years of age

Exclusion Criteria:

A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:

  1. History of CFE or bypass in affected limb
  2. Thrombosis of affected CFA
  3. Aneurysm in the common femoral artery of target limb
  4. Known target lesion restenosis (re-narrowing of the artery to ≥50% following the alleviation of a previous narrowing within 3 months)
  5. Any preceding percutaneous cardiovascular intervention within 2 weeks
  6. Inability to tolerate DAPT
  7. Known coagulopathy or bleeding diathesis, thrombocytopenia with platelet count <100,000/µL
  8. Uncontrolled diabetes (HbA1c ≥10.0%)
  9. Non-ambulatory
  10. Extensive tissue loss requiring amputation or salvageable only with complex foot reconstruction or non-traditional transmetatarsal amputations
  11. MI within 6 weeks (defined as presumed ischemic symptoms (chest pain, ST-segment deviation and troponin higher than 2 times the upper limit of normal))
  12. Stroke within 3 months (defined as sudden transient or irreversible focal neurological deficit resulting from a cerebrovascular cause)
  13. Pregnant

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur actif: Shockwave Catheter

Shockwave™ Intravenous Lithotripsy (IVL)+ DCB (Drug Coated Balloon)

Shockwave™ IVL + DCB procedure

Comparateur actif: surgical endarterectomy

Surgery should be performed with patch angioplasty, with or without profunda femoris endarterectomy.

Standard CFA endarterectomy

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Revascularisation des lésions cibles conduites cliniquement (CDTLR (revascularisation répétée axée sur les symptômes de la lésion de l'indice)))
Délai: Date de procédure jusqu'à un an après l'opération
Date de procédure jusqu'à un an après l'opération
Resténose à ≥ 50% de la lésion cible sur l'angiographie ou l'échographie de suivi
Délai: Date de procédure jusqu'à un an après l'opération
Date de procédure jusqu'à un an après l'opération
Liberté de la mort périopératoire
Délai: Date de procédure jusqu'à 30 jours après l'opération
Date de procédure jusqu'à 30 jours après l'opération
Liberté des principaux événements cardiovasculaires indésirables (mace (AVC, infarctus du myocarde (IM), mort cardiovasculaire)))
Délai: Date de procédure jusqu'à 30 jours après l'opération
Date de procédure jusqu'à 30 jours après l'opération
Freedom from major adverse events
Délai: Procedure date through 6 months post-op
  1. Acute occlusion of the target lesion

  2. Flow-limiting dissection of the target lesion

  3. Symptomatic thrombus or embolus in treated limb requiring treatment

  4. Unplanned percutaneous/surgical revascularization or amputation above the ankle of the treated limb

  5. Access/surgical site complications

    1. Bleeding events (specify Bleeding Academic Research Consortium (BARC) type - see Appendix 18.2)
    2. Surgical site infection requiring medication or surgery, wound dehiscence, patch/arterial infection, lymphatic leak requiring surgery
Procedure date through 6 months post-op

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Mortalité
Délai: Date de procédure jusqu'à un an après l'opération
Date de procédure jusqu'à un an après l'opération
Transfusion sanguine peropératoire> 4 minutes
Délai: Intra-op
Intra-op
Durée de procédure (minutes)
Délai: Intra-op
Intra-op
Durée du séjour (jours)
Délai: Date de procédure jusqu'à 1 an après l'opération
Date de procédure jusqu'à 1 an après l'opération
Anémie postopératoire nécessitant une transfusion sanguine
Délai: Date de procédure jusqu'à 30 jours après l'opération
Date de procédure jusqu'à 30 jours après l'opération
Réadmissions
Délai: 30 jours après l'opération, 30 jours après la sortie
30 jours après l'opération, 30 jours après la sortie
Retour à la salle d'opération / suite d'angiographie
Délai: 30 jours après l'opération
30 jours après l'opération
Rutherford Chronic Limb Ischemia (CLI) Category
Délai: 30 days post-op, 3 months post-op, 6 months post-op, 1 year post-op

https://www.ncbi.nlm.nih.gov/books/NBK553864/table/ch20.Tab2/#

Stage 0 - Asymptomatic. Stage 1 - Mild claudication - Completes treadmill exercise; Ankle Pressure (AP) after exercise >50 mmHg but at least 20 mmHg lower than resting value.

Stage 2 - Moderate claudication - Between categories 1 and 3. Stage 3 - Severe claudication - Cannot complete standard treadmill exercise and AP after exercise <50 mm Hg.

Stage 4 - Ischemic rest pain - Resting AP <40 mm Hg, flat or barely pulsatile ankle or metatarsal pulse volume recording (PVR); Toe Pressure (TP) < 30 mm Hg.

Stage 5 - Minor tissue loss-nonhealing ulcer, focal gangrene with diffuse pedal ischemia- Resting AP < 60 mm Hg, ankle or metatarsal PVR flat or barely pulsatile; TP < 40 mm Hg Stage 6 - Major tissue loss-extending above TM level, functional foot no longer salvageable - Same as category 5

30 days post-op, 3 months post-op, 6 months post-op, 1 year post-op
Treatment satisfaction and quality of life (PAQ)
Délai: Pre-op, 30 days post-op, 6 months post-op, 1 year post-op

Measured by the Peripheral Artery Questionnaire (PAQ), a 20-question questionnaire measuring peripheral vascular disease affect on quality of life. Questionnaires may be completed in-person or via phone call conducted by the study coordinator.

Pre-op, 30 days post-op, 6 months post-op, 1 year post-op
Access/surgical site complications
Délai: 30 days post-op, 6 months post-op
  1. Superficial wound infection
  2. Deep wound infection
  3. Wound dehiscence
  4. Pseudoaneurysm identified on physical exam, imaging or angiography
  5. Hematoma identified on physical exam, imaging or angiography
30 days post-op, 6 months post-op
Pneumonia (number of cases)
Délai: Procedure date through 30 days post-op

Patients must meet criteria from both sections:

Radiology: One definitive chest radiological exam (x-ray or CT) with at least one of the following:

  • New or progressive and persistent infiltrate
  • Consolidation or opacity

Patients with underlying pulmonary or cardiac disease require two serial chest radiological exams (x-ray or CT) taken no less than 12 hours apart, but no more than 7 days apart.

Signs/Symptoms/Laboratory: at least one of the following:

  • Fever (>38 C) with no other recognized cause

  • Leukopenia (<4000 WBC/mm3) or leukocytosis (≥12,000 WBC/mm3)

  • For adults ≥ 70 years old, altered mental status with no other recognized cause and at least one of the following:

    1. 5% Bronchoalveolar lavage (BAL)
    2. Positive growth in blood culture not related to another source of infection
    3. Positive growth in culture of pleural fluid
    4. Positive quantitative culture from minimally contaminated lower respiratory tract (LRT) specimen
Procedure date through 30 days post-op
Prolonged intubation
Délai: Procedure date through 30 days post-op

Intubation greater than 48 hours postoperatively

Procedure date through 30 days post-op
Urinary tract infection
Délai: Procedure date through 30 days post-op

Must meet one of the following TWO criteria within 30 days of the operation:

  • fever (>38C)
  • urgency
  • frequency
  • dysuria
  • suprapubic tenderness

AND urine culture of >105 colonies/mL urine with no more than two species of organisms

OR two of the following:

  • fever (>38C)
  • urgency
  • frequency
  • dysuria
  • suprapubic tenderness

AND any of the following:

  • dipstick test positive for leukocyte esterase and/or nitrite
  • pyuria (>10WBCs/mL or >3 WBC/hpf of unspun urine)
  • organisms seen on Gram stain of unspun urine
  • two urine cultures with repeated isolation of the same uropathogen with >102 colonies/mL urine in non-voided specimen
  • urine culture with <105 colonies/mL urine of single uropathogen in patient being treated with appropriate antimicrobial therapy
  • physician's diagnosis
  • physician institutes appropriate antimicrobial therapy
Procedure date through 30 days post-op
Sepsis
Délai: Procedure date through 30 days post-op

The disorder spectrum spans from relatively mild physiologic abnormalities to septic shock. The most significant level is reported using the following criteria: SIRS (Systemic Inflammatory Response Syndrome), clinically recognized by the presence of two or more of the following in the same time frame:

Temp >38 degrees C or 90 bpm RR >20 breaths/min or PaCO2 12,000 cell/mm3, 10% immature (band) forms anion gap acidosis. Report if the patient has clinical signs and symptoms of SIRS listed above and meets either A or B:

A. One of the following:

  • Positive blood culture
  • Clinical documentation of purulence or positive culture

B. Suspected pre-operative infection or bowel infarction leading to the surgical procedure. Procedural findings must confirm this suspected diagnosis with one or more of the following:

  • Confirmed infarcted bowel requiring resection
  • Purulence in the operative site
  • Enteric contents in the operative site
  • Positive intra-operative cultures
Procedure date through 30 days post-op
Septic shock
Délai: Procedure date through 30 days post-op

Report this variable if the patient has sepsis AND documented organ and/or circulatory dysfunction. Examples of organ dysfunction include: oliguria, acute alteration in mental status, acute respiratory distress. Examples of circulatory dysfunction include: hypotension, requirement of inotropic or vasopressor agents. The presence of pneumatosis along with the presence of SIRS is assigned.

Procedure date through 30 days post-op
Graft failure
Délai: Procedure date through 30 days post-op

Mechanical failure of an extracardiac graft or prosthesis including myocutaneous flaps and skin grafts requiring return to the operating room, interventional radiology or a balloon angioplasty within 30 days of the operation.

Procedure date through 30 days post-op
Cardiac arrest
Délai: Procedure date through 30 days post-op

The absence of cardiac rhythm or presence of chaotic cardiac rhythm, intraoperatively or postoperatively, which results in a cardiac arrest requiring the initiation of CPR, which includes chest compressions. Patients are included who are in a pulseless VT or Vfib in in which defibrillation is performed and PEA arrests requiring chest compressions. Patients with automated implantable cardioverter defibrillator (AICD) that fire but the patient has no loss of consciousness should be excluded.

Procedure date through 30 days post-op
Myocardial infarction
Délai: Procedure date through 30 days post-op

Documentation of one or more of the following changes indicative of acute MI:

  • ST elevation >1mm in two or more contiguous leads
  • New left bundle branch block
  • New q-wave in two or more contiguous leads
  • New elevation in troponin greater than 3 times the upper level o f the reference range in the setting of suspected myocardial ischemia
Procedure date through 30 days post-op
Acute kidney injury
Délai: Procedure date through 30 days post-op

In a patient who did not require dialysis preoperatively, worsening of renal dysfunction postoperatively requiring hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration, or ultrafiltration

Procedure date through 30 days post-op
Dialysis
Délai: Procedure date through 30 days post-op

Initiation of hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration or ultrafiltration in a patient not previously on said therapy preoperatively

Procedure date through 30 days post-op
Deep vein thrombosis
Délai: Procedure date through 30 days post-op

New diagnosis of blood clot or thrombus within the venous system (superficial or deep) which may be coupled with inflammation and requires treatment. Must be noted within 30 days after the principal operative procedure AND one of the following A or B below:

A.New Diagnosis of a [new] venous thrombosis (superficial or deep), confirmed by a duplex, venogram, CT scan, or any other definitive imaging modality (including direct pathology examination such as autopsy) AND the patient must be treated with anticoagulation therapy and/or placement of a vena cava filter or clipping of the vena cava, or the record indicates that treatment was warranted but there was no additional appropriate treatment option available.

B. As per (A) above, but the patient or decisionmaker has refused treatment. There must be documentation in the medical record of the [patient's] refusal of treatment.

Procedure date through 30 days post-op
Pulmonary embolism
Délai: Procedure date through 30 days post-op

Lodging of a blood clot in the pulmonary artery with subsequent obstruction of blood supply to the lung parenchyma. The blood clots usually originate from the deep leg veins or pelvic venous system. Since there are not always preoperative studies proving that a clot or thrombus was not present preoperatively, the technical specification of the variable requires only a "new diagnosis"- in other words the clot or thrombus was not previously known. A pulmonary embolism must be noted within 30 days after the principal operative procedure AND the following criteria, A AND B below:

A. New diagnosis of a new blood clot in a pulmonary artery

AND

B. The patient has a V-Q scan interpreted as high probability of pulmonary embolism or a positive CT exam, TEE, pulmonary arteriogram, CT angiogram, or any other definitive imaging modality (including direct pathology examination such as autopsy

Procedure date through 30 days post-op

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Chercheur principal: Sameh Sayfo, MD, Baylor Scott & White The Heart Hospital - Plano
  • Chercheur principal: John Kedora, MD, Baylor Scott & White The Heart Hospital - Plano

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

7 mars 2024

Achèvement primaire (Réel)

3 novembre 2026

Achèvement de l'étude (Estimé)

30 décembre 2026

Dates d'inscription aux études

Première soumission

1 octobre 2024

Première soumission répondant aux critères de contrôle qualité

11 février 2025

Première publication (Réel)

17 février 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

6 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 novembre 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 021-263

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Oui

produit fabriqué et exporté des États-Unis.

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner